Adam Pennycuick
@adampennycuick.bsky.social
Lung Oncologist @UCLH | Bioinformatician @lungsforliving | Founder @oslrapp researchbriefing.com | Early lung cancer, prevention, MedEd, all things data 👨💻
AlphaMissense promises powerful AI for pathogenic variant identification. Is it clinically useful? Smart validation approach here against known signatures ascopubs.org/doi/10.1200/... Found with researchbriefing.com
ascopubs.org
June 30, 2025 at 8:01 AM
AlphaMissense promises powerful AI for pathogenic variant identification. Is it clinically useful? Smart validation approach here against known signatures ascopubs.org/doi/10.1200/... Found with researchbriefing.com
Could we “see” intratumoral CD4 cells in vivo with PET? That’s the promise of this novel tracer. Very cool if it works www.science.org/doi/10.1126/... Found with researchbriefing.com
www.science.org
June 27, 2025 at 8:00 AM
Could we “see” intratumoral CD4 cells in vivo with PET? That’s the promise of this novel tracer. Very cool if it works www.science.org/doi/10.1126/... Found with researchbriefing.com
Night shifts increase lung cancer risk - and there's more to it than smoking. Very interesting BioBank analysis here academic.oup.com/sleep/advanc.... Found with researchbriefing.com
June 12, 2025 at 8:01 AM
Night shifts increase lung cancer risk - and there's more to it than smoking. Very interesting BioBank analysis here academic.oup.com/sleep/advanc.... Found with researchbriefing.com
Immunotherapy tox is not always bad; can lead to better outcomes. More data on this in the post-CRT NSCLC setting bmcpulmmed.biomedcentral.com/articles/10.... Found with researchbriefing.com
Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC - BMC Pulmonary Medicine
Background Consolidative PD-L1 inhibitors after concurrent chemoradiotherapy (cCRT) have become standard care in locally advanced non-small cell lung cancer (LA-NSCLC). However, the correlation…
bmcpulmmed.biomedcentral.com
June 11, 2025 at 8:01 AM
Immunotherapy tox is not always bad; can lead to better outcomes. More data on this in the post-CRT NSCLC setting bmcpulmmed.biomedcentral.com/articles/10.... Found with researchbriefing.com
This is a compelling vision of how AI agents will improve our treatment decisions in future www.nature.com/articles/s43.... Impressive progress but still a way from the clinic. Found with researchbriefing.com
Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology - Nature Cancer
Ferber et al. present an autonomous artificial intelligence agent system for deployment of specialized medical oncology computational tools, validating their system across various clinical scenarios…
www.nature.com
June 10, 2025 at 8:01 AM
This is a compelling vision of how AI agents will improve our treatment decisions in future www.nature.com/articles/s43.... Impressive progress but still a way from the clinic. Found with researchbriefing.com
I’ve always struggled with dermatology. Never good at identifying skin problems. Now AI can do it for us, and better www.nature.com/articles/s41... - need this in EPIC ASAP! Found with researchbriefing.com
A multimodal vision foundation model for clinical dermatology - Nature Medicine
Trained on large and multicenter datasets with different imaging modalities, a foundation model is shown to have strong performance on the full spectrum of clinically relevant tasks and to increase…
www.nature.com
June 9, 2025 at 8:01 AM
I’ve always struggled with dermatology. Never good at identifying skin problems. Now AI can do it for us, and better www.nature.com/articles/s41... - need this in EPIC ASAP! Found with researchbriefing.com
First line ipi nivo for mNSCLC. 19% still responding at 6y. We don’t use this combo but I’m sure there are some patients who would benefit, if we could target them better www.esmoopen.com/article/S205... Found with researchbriefing.com
www.esmoopen.com
June 3, 2025 at 8:02 AM
First line ipi nivo for mNSCLC. 19% still responding at 6y. We don’t use this combo but I’m sure there are some patients who would benefit, if we could target them better www.esmoopen.com/article/S205... Found with researchbriefing.com
Cancers are complex. This study shows moving from simple biomarkers to more complex models can improve outcomes www.nature.com/articles/s41... Found with researchbriefing.com
Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer - npj Precision Oncology
npj Precision Oncology - Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer
www.nature.com
June 2, 2025 at 8:01 AM
Cancers are complex. This study shows moving from simple biomarkers to more complex models can improve outcomes www.nature.com/articles/s41... Found with researchbriefing.com
Patients with COPD do better on immunotherapy www.nature.com/articles/s41... Found with researchbriefing.com
COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors - Scientific Reports
Scientific Reports - COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors
www.nature.com
May 20, 2025 at 8:00 AM
Patients with COPD do better on immunotherapy www.nature.com/articles/s41... Found with researchbriefing.com
In genomics we tend to think in 1D sequences. Great study shows we need think in 3D www.nature.com/articles/s41... Found with researchbriefing.com
Three-dimensional genome landscape of primary human cancers - Nature Genetics
This study characterizes the three-dimensional (3D) genome architecture of 15 primary human cancer types from The Cancer Genome Atlas. The analyses identify different archetypes of enhancer usage and…
www.nature.com
May 14, 2025 at 8:00 AM
In genomics we tend to think in 1D sequences. Great study shows we need think in 3D www.nature.com/articles/s41... Found with researchbriefing.com
How old you look is a better predictor of outcome than how old you are. Another smart AI application shows prognostic value of FaceAge predictor in cancer patients buff.ly/e275kVV Found with researchbriefing.com
www.thelancet.com
May 13, 2025 at 8:01 AM
How old you look is a better predictor of outcome than how old you are. Another smart AI application shows prognostic value of FaceAge predictor in cancer patients buff.ly/e275kVV Found with researchbriefing.com
Spatial profiling of precancerous lung lesions identifies TIM3 as a potential interception target www.sciencedirect.com/science/arti.... Fantastic study. Found with researchbriefing.com
www.sciencedirect.com
May 12, 2025 at 8:02 AM
Spatial profiling of precancerous lung lesions identifies TIM3 as a potential interception target www.sciencedirect.com/science/arti.... Fantastic study. Found with researchbriefing.com
Can we improve immunotherapy responses by depleting regulatory T-cells? Encouraging data in GBM www.cell.com/immunity/ful... Found with researchbriefing.com
www.cell.com
April 30, 2025 at 8:01 AM
Can we improve immunotherapy responses by depleting regulatory T-cells? Encouraging data in GBM www.cell.com/immunity/ful... Found with researchbriefing.com
Can we predict patient outcomes by… asking them? Longitudinal analysis of PRO data suggests we can aacrjournals.org/clincancerre... Found with researchbriefing.com
aacrjournals.org
April 29, 2025 at 8:01 AM
Can we predict patient outcomes by… asking them? Longitudinal analysis of PRO data suggests we can aacrjournals.org/clincancerre... Found with researchbriefing.com
Love this use of AI. Reviewed >600k oncology patient messages to find their main care issues. Great to focus future improvements jamanetwork.com/journals/jam... Found with researchbriefing.com
jamanetwork.com
April 28, 2025 at 8:01 AM
Love this use of AI. Reviewed >600k oncology patient messages to find their main care issues. Great to focus future improvements jamanetwork.com/journals/jam... Found with researchbriefing.com
Clonal haematopoeisis; important in ageing and now associated with worse outcomes when infiltrating tumours. More great work from the TRACERx team www.nejm.org/doi/10.1056/... Found with researchbriefing.com
www.nejm.org
April 25, 2025 at 8:00 AM
Clonal haematopoeisis; important in ageing and now associated with worse outcomes when infiltrating tumours. More great work from the TRACERx team www.nejm.org/doi/10.1056/... Found with researchbriefing.com
In scRNAseq how do you find tumour cells? This approach makes sense to me, using CNA profiles inferred from the transcriptome academic.oup.com/bib/article/... Found with researchbriefing.com
academic.oup.com
April 24, 2025 at 8:01 AM
In scRNAseq how do you find tumour cells? This approach makes sense to me, using CNA profiles inferred from the transcriptome academic.oup.com/bib/article/... Found with researchbriefing.com
Antibiotics can affect immunotherapy efficacy via the microbiome. Should be used with caution. Helpful and detailed guide: ascopubs.org/doi/10.1200/... Found with researchbriefing.com
ascopubs.org
April 23, 2025 at 8:11 AM
Antibiotics can affect immunotherapy efficacy via the microbiome. Should be used with caution. Helpful and detailed guide: ascopubs.org/doi/10.1200/... Found with researchbriefing.com
Adding RT to peri-op chemoIO improves MPR but not OS/PFS www.jto.org/article/S155... Found with researchbriefing.com
www.jto.org
April 14, 2025 at 8:00 AM
Adding RT to peri-op chemoIO improves MPR but not OS/PFS www.jto.org/article/S155... Found with researchbriefing.com
MetaGP - medical foundation model improves diagnostic performance of doctors buff.ly/WzRk39a Found with researchbriefing.com
www.sciencedirect.com
April 8, 2025 at 8:00 AM
MetaGP - medical foundation model improves diagnostic performance of doctors buff.ly/WzRk39a Found with researchbriefing.com
This got me thinking about neoadjuvant trial design. Phase II neoadj EGFR inhibitor declared a success due to high conversion rate to resectability in unresectable stage III disease www.nature.com/articles/s41... (1/2)
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial - Nature Communications
Aumolertinib is a third generation EGFR tyrosine kinase inhibitors, approved for use in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Here, the authors report a phase 2…
buff.ly
April 7, 2025 at 8:00 AM
This got me thinking about neoadjuvant trial design. Phase II neoadj EGFR inhibitor declared a success due to high conversion rate to resectability in unresectable stage III disease www.nature.com/articles/s41... (1/2)
Exosomes are definitely interesting for early cancer detection. AI-powered exosome detection using microfluidics seems like a smart approach buff.ly/rKqTrXu Found with researchbriefing.com
pubs.acs.org
April 4, 2025 at 8:01 AM
Exosomes are definitely interesting for early cancer detection. AI-powered exosome detection using microfluidics seems like a smart approach buff.ly/rKqTrXu Found with researchbriefing.com
Can LLMs design proteins now? Enzymes designed with natural language prompts... incredible... buff.ly/nSvYH9Z Found with researchbriefing.com
Toward De Novo Protein Design from Natural Language
De novo protein design represents a fundamental pursuit in protein engineering, yet current deep learning approaches remain constrained by their narrow design scope. Here we present Pinal, a…
www.biorxiv.org
April 3, 2025 at 8:00 AM
Can LLMs design proteins now? Enzymes designed with natural language prompts... incredible... buff.ly/nSvYH9Z Found with researchbriefing.com
People at germline risk of autoimmune diseases also at risk of ICI tox. Makes sense - could lead to better personalisation in future buff.ly/qj0KnOh Found with researchbriefing.com
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Introduction Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors, but they also commonly cause immune-related adverse events (irAEs).…
jitc.bmj.com
April 2, 2025 at 8:00 AM
People at germline risk of autoimmune diseases also at risk of ICI tox. Makes sense - could lead to better personalisation in future buff.ly/qj0KnOh Found with researchbriefing.com
Could protein translation defects lead to more immunogenic cancers? Could we exploit this vulnerability? Study of key translation proteins suggests so buff.ly/C6PKdF4 Found with researchbriefing.com
www.sciencedirect.com
April 1, 2025 at 8:00 AM
Could protein translation defects lead to more immunogenic cancers? Could we exploit this vulnerability? Study of key translation proteins suggests so buff.ly/C6PKdF4 Found with researchbriefing.com